Search

Your search keyword '"Caselli, Gianfranco"' showing total 212 results

Search Constraints

Start Over You searched for: Author "Caselli, Gianfranco" Remove constraint Author: "Caselli, Gianfranco"
212 results on '"Caselli, Gianfranco"'

Search Results

1. Ferulated Poly(vinyl alcohol) based hydrogels

2. A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19

3. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models

6. A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19

10. Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

12. CR13626: a novel oral brain penetrant tyrosine kinase inhibitor that reduces tumor growth and prolongs survival in a mouse model of glioblastoma

17. CR13626: a novel oral brain penetrant tyrosine kinase inhibitor that reduces tumor growth and prolongs survival in a mouse model of glioblastoma

18. COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19

21. Abstract 2208: Combination of the EP4 antagonist CR6086 and anti-PD-1 monoclonal antibody inhibits tumor growth in a microsatellite stable colorectal cancer in mice

22. Improved efficacy, tolerance, safety, and abuse liability profile of the combination of CR4056 and morphine over morphine alone in rodent models

27. Toxicity and Local Tolerance of COVID- e Vax, a Plasmid DNA Vaccine for SARS-CoV-2, Delivered by Electroporation.

28. Thioredoxin, a Redox Enzyme Released in Infection and Inflammation, Is a Unique Chemoattractant for Neutrophils, Monocytes, and T Cells

31. Additional file 3: of Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

32. Additional file 1: of Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

33. Additional file 4: of Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

34. Additional file 2: of Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

37. Functionalization of protein hexahistidine tags by functional nanoreactors

38. Nanoreactors for the multi-functionalization of poly-histidine fragments

43. Development of subnanomolar-affinity serotonin 5-HT4 receptor ligands based on quinoline structures

44. Poly-histidine grafting leading to fishbone-like architectures

45. Development of Imidazole-Reactive Molecules Leading to a New Aggregation-Induced Emission Fluorophore Based on the Cinnamic Scaffold

47. CR4056, a powerful analgesic imidazoline-2 receptor ligand, inhibits the inflammation-induced PKCε phosphorylation and membrane translocation in sensory neurons.

48. Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis

49. Multivalent ligands for the serotonin 5-HT4 receptor

Catalog

Books, media, physical & digital resources